Mood swings lasting for weeks, excessive energy followed by a collapse, an unpredictable daily life: when a doctor mentions a mood stabilizer, the question of choice arises quickly. These medications, known as mood stabilizers, do not all work the same way and do not target the same symptoms. Understanding their differences helps to ask the right questions during the consultation.
Mood stabilizer: how the type of episode affects treatment choice
A point rarely discussed in consumer guides: the prescribed mood stabilizer depends less on the overall diagnosis than on the type of episode to be prevented. Two people with bipolar disorder may receive very different medications.
Let’s take a concrete example. A person whose relapses are mainly depressive may be offered lamotrigine, which is indicated for the prevention of severe depressive episodes in patients with type I bipolar disorder with predominant depressive polarity. In contrast, lamotrigine does not treat acute mania. For someone experiencing intense manic phases, lithium or an anticonvulsant like valproate would be more suitable.
As detailed in The Living Web article, the first useful question to ask the prescriber is: what type of episode is this treatment primarily aimed at preventing? The answer already guides a significant part of the choice.
Lithium, valproate, or lamotrigine: concrete criteria to understand the differences
You may have noticed that the leaflets for these medications all seem to mention bipolar disorder without clearly specifying what distinguishes them? Here are the key points to discuss with a doctor.
Lithium and its monitoring constraints
Lithium remains the reference mood stabilizer. It acts on both manic and depressive episodes, and it is prescribed for both acute treatment and relapse prevention. Its particularity: lithium requires regular blood tests, especially at the beginning and after each dose change.
This monitoring is not a formality. The margin between the effective dose and the toxic dose is narrow. Dehydration, vomiting, diarrhea, or the intake of certain medications (including common non-steroidal anti-inflammatory drugs) can alter lithium concentration in the blood and increase the risk of toxicity.
If access to blood tests or consultations is complicated (geographical distance, professional constraints), it should be discussed before starting treatment. The feasibility of monitoring is a real criterion for choice, not a logistical detail.
Valproate: effective but regulated
Valproate (and valpromide) is indicated for the treatment of manic episodes and as a long-term mood stabilizer in case of lithium failure or intolerance. It is particularly monitored in women of childbearing age due to significant teratogenic risks. A pregnancy prevention program strictly regulates its prescription in this population.
Lamotrigine: a specific role
Unlike the previous two, lamotrigine is primarily used as a maintenance treatment to prevent the recurrence of depressive episodes. It does not cover the manic phase. Its side effect profile also differs: no blood monitoring as stringent as lithium, but a gradual increase in dosage to limit the risk of skin reactions.
Side effects of stabilizers: what weighs in the daily choice
The profile of side effects directly influences long-term treatment adherence. An effective but poorly tolerated medication is often abandoned. Here are the most common side effects by class:
- Lithium: hand tremors, weight gain, increased thirst, thyroid and renal disorders to monitor long-term
- Valproate: weight gain, digestive disorders, drowsiness, hepatic risks requiring biological monitoring
- Lamotrigine: risk of skin reaction (hence the slow titration), headaches, dizziness
- Atypical antipsychotics (olanzapine, quetiapine, aripiprazole): sometimes significant weight gain, metabolic disorders, sedation
Report any new medication to the prescriber, even if taken occasionally, remains a safety rule applicable to all mood stabilizers. Drug interactions are common in this class.
Pregnancy and mood stabilizers: a discussion to anticipate
Why address this topic even before choosing a treatment? Because the pregnancy plan can modify the choice of stabilizer from the outset. Some molecules, like valproate, are contraindicated during pregnancy due to malformative and neurodevelopmental risks for the child.
This constraint does not only concern pregnant women. Women of childbearing age should discuss contraception and parenting plans with their psychiatrist before starting treatment. Lithium also carries risks, albeit different, which require case-by-case evaluation.
Addressing this point in advance helps avoid an urgent treatment change, which is always more destabilizing than a calm planning.
Concrete questions to ask before starting a mood stabilizer treatment
Rather than a list of generic recommendations, here are the questions that can transform a consultation into a real exchange about medication choice:
- What type of episode is this treatment aimed at preventing (mania, depression, both)?
- Are blood tests necessary and how often?
- What common medications should I avoid or report during treatment?
- What is the expected duration before assessing effectiveness?
- What side effects warrant a quick call or consultation?
No mood stabilizer is universally effective: the choice depends on the clinical profile, individual tolerance, and monitoring constraints. A treatment adjusted with the doctor, reevaluated over time, remains the best guarantee of stability.
